Made on
Tilda
Multiple sclerosis treatment often continues for many years or even decades. Choosing the first disease-modifying therapy is therefore only the beginning of a long-term strategy. Treatment may later need to change because of new disease activity, adverse effects, increasing safety risks, pregnancy planning or a change in the clinical course of MS.
Switching treatment does not necessarily mean that the original choice was wrong. In the same patient, the balance between efficacy and safety can change substantially with age, disease duration and previous treatment exposure.
A confirmed relapse occurring after the treatment has had sufficient time to develop its expected therapeutic effect may indicate inadequate control of inflammatory disease activity.
New or enlarging T2 lesions and gadolinium-enhancing lesions may indicate subclinical disease activity even when the patient feels clinically stable.
Slow worsening of walking, balance, hand function or cognition without an obvious relapse requires assessment for PIRA and possible evolution toward a progressive phenotype.
Recurrent infections, significant lymphopenia, falling immunoglobulin levels, liver abnormalities, increasing PML risk or other complications can change the benefit-risk balance.
Even an effective treatment may need to be replaced if adverse effects substantially impair quality of life or make regular treatment difficult.
Pregnancy planning, new comorbidities, changes in drug availability, insurance coverage or treatment schedule may also require a new therapeutic strategy.
No single rule states that every new MRI lesion automatically represents treatment failure. However, MRI activity should not be ignored even when no clinical relapse has occurred.
The interpretation depends on when the lesion probably developed, which treatment is being used, its location, previous disease activity, earlier MRI scans and whether other signs of inadequate response are present.
In some situations, one lesion may lead to closer follow-up rather than an immediate treatment change.
Several new lesions, recurrent MRI activity or the combination of MRI changes with clinical relapses provides a much stronger argument for changing treatment.
A 2024 real-world study of clinically stable patients receiving low- or moderate-efficacy DMTs found that escalation in the presence of isolated MRI activity was associated with a lower subsequent relapse risk, particularly when two or more new T2 lesions were present.
This is evidence from a real-world study, not a universal numerical threshold that mandates treatment switching for every patient.
After starting or switching a DMT, a new MRI reference point is usually established. In many monitoring strategies, MRI is repeated after several months, often approximately 4–6 months, with subsequent imaging intervals based on disease activity, treatment type and previous results.
Gadolinium is not required for every routine follow-up scan. With a standardized imaging protocol, comparison of new T2/FLAIR lesions often allows disease activity to be monitored without routine contrast administration.
A substantial proportion of disability accumulation in MS can occur independently of clinical relapses. This is referred to as PIRA — progression independent of relapse activity.
Gradual worsening of walking, movement speed, hand function, balance, endurance or cognition.
The absence of new conventional T2 lesions does not exclude gradual accumulation of disability.
Weakness, spasticity, pain, orthopaedic problems, deconditioning, medication effects and other diseases can also worsen function.
When inflammatory disease activity is confirmed during a moderate-efficacy treatment, switching to a higher-efficacy DMT is often considered.
The aim is to provide stronger suppression of relapses and new MRI activity.
If disease activity is controlled but tolerability, safety or convenience is problematic, switching to a treatment with similar efficacy but a different risk profile may be appropriate.
In selected patients, particularly with increasing age and prolonged stability, a lower-intensity treatment strategy, longer treatment intervals or a less immunosuppressive approach may be considered.
There is no universal washout period that applies to every MS treatment. In some situations, an unnecessary gap increases the risk of disease activity. In others, excessive overlap of immune effects may increase infection or toxicity risks.
| Current treatment | Main issue when switching | General principle |
|---|---|---|
|
Interferon beta and glatiramer acetate | There is usually no prolonged clinically significant immunosuppression after stopping. | A prolonged washout is generally unnecessary. Timing of the next DMT is mainly determined by screening, laboratory tests and vaccination requirements. |
|
Fumarates
dimethyl fumarate, diroximel fumarate | The main concern is significant or prolonged lymphopenia in some patients. | With acceptable blood counts, a long gap is usually unnecessary. When significant lymphopenia is present, timing depends on its severity, cell recovery, infection risk and the next treatment. |
| Teriflunomide | The drug can remain in the body for a prolonged period. | Accelerated elimination may be required in selected situations, including pregnancy planning or serious toxicity. It is not automatically required before every treatment switch. |
|
S1P receptor modulators
fingolimod, siponimod, ozanimod, ponesimod | Inflammatory disease activity may return after treatment withdrawal. Rebound is particularly well described after fingolimod. | Unnecessarily prolonged treatment gaps are generally avoided. Lymphocyte counts, infection risk and the mechanism of the next DMT must still be considered. |
| Natalizumab | Disease activity may return rapidly after withdrawal. At the same time, PML risk and possible carry-over PML must be considered. | The exit strategy should ideally be planned before natalizumab is stopped. Current evidence supports a relatively short transition to anti-CD20 therapy in many cases, but timing is individualized. |
|
Anti-CD20 therapies
ocrelizumab, ofatumumab, rituximab | Prolonged biological effect, infection risk, reduced immunoglobulins and reduced vaccine responses. | Complete B-cell repopulation is not universally required before every subsequent therapy. The decision considers the reason for switching, IgG, infections, blood counts, vaccination and the next treatment mechanism. |
| Cladribine | Cladribine is an immune-reconstitution treatment whose effect continues after the short treatment courses have finished. | Further therapy may be considered if disease activity returns, tolerability becomes problematic or the clinical situation changes. Timing depends on time since treatment, lymphocyte counts and cumulative immune effects. |
| Alemtuzumab | Long-lasting immune reconstitution and the possibility of delayed autoimmune complications. | Subsequent therapy is highly individualized. Evidence on optimal sequencing is more limited than for many other DMTs. |
After some DMTs are stopped, inflammatory disease activity can return rapidly. In some patients the recurrence can be severe, with significant relapses and multiple new MRI lesions.
After natalizumab is stopped, the risk of renewed disease activity increases as the period without effective subsequent therapy becomes longer.
When treatment is being stopped because of JCV/PML risk, the strategy must minimize both recurrent MS activity and the possibility of carry-over PML.
Rebound is especially well described after fingolimod withdrawal. The next treatment and its timing should therefore be planned before the current therapy is stopped.
High efficacy does not remove the need to reassess treatment safety. This becomes particularly important after many years of therapy and as the patient grows older.
Recurrent or severe infections may require a change in treatment intensity or a switch to a different mechanism of action.
During long-term B-cell depletion, IgG levels, infection frequency and the clinical context may be more relevant than B-cell counts alone.
Persistent significant lymphopenia may become a reason to switch therapy or alter the timing of the next treatment.
JCV serostatus, antibody index, treatment duration and prior immunosuppression are considered when estimating PML risk.
On average, focal inflammatory activity declines with age, while infection and other immunosuppression-related risks may increase.
Cancer, haematological, liver, cardiovascular and other medical conditions may change which DMT is appropriate.
Pregnancy is best planned together with the MS treatment strategy. For patients with active disease, simply stopping an effective treatment for a prolonged period may carry more risk than a planned transition.
In highly active MS, a prolonged interruption of natalizumab before or early in pregnancy may significantly increase the risk of relapse.
In selected patients, treatment may be continued during pregnancy according to an individualized strategy, balancing maternal disease control against potential effects of later fetal exposure.
These therapies, including fingolimod, are not used during pregnancy. In patients with active disease, a replacement strategy should be established before treatment is stopped to reduce rebound risk.
Current evidence supports the use of intravenous anti-CD20 therapy before conception in selected women with active MS, because the biological effect continues after the infusion.
Exact timing is individualized and should also take the product information for the specific therapy into account.
These treatments have some of the most reassuring experience during the reproductive period and may be useful in selected clinical situations.
A large French registry study published in 2025 showed that changes in DMT strategy around pregnancy can influence relapse risk. The greatest increases in risk were observed after prolonged natalizumab interruption and in women previously treated with fingolimod.
A strategy using intravenous anti-CD20 therapy before pregnancy was associated with the lowest relapse risk in this observational study.
Blood biomarkers are becoming an additional tool for monitoring multiple sclerosis, but they do not replace clinical assessment and MRI.
Higher NfL may reflect increased neuroaxonal injury. Levels often increase during inflammatory MS activity, but NfL is not specific to multiple sclerosis.
Serial standardized measurements, interpreted according to age and appropriate reference values, are generally more informative than one isolated result.
GFAP reflects astroglial activity and is being investigated as a potential biomarker of progressive disease biology.
Its role in routine treatment-switching decisions is currently less established than that of NfL.
When function gradually worsens, the key question is whether inflammatory activity is still present or progression is occurring without relapses. These situations require different treatment reasoning.
When relapses or new MRI activity continue, the inflammatory component remains a treatment target.
DMT selection depends on local regulatory indications, previous therapies and the individual safety profile.
Until recently, disease-modifying options for non-relapsing SPMS were very limited.
In June 2026, tolebrutinib (Cenrifki) was authorised in the European Union for adults with SPMS without relapses during the previous two years.
With increasing age, the balance between treatment benefit and risk may change. Modern MS management therefore includes not only escalation, but also the possibility of de-escalation in carefully selected patients.
The DISCOMS trial included patients aged 55 years or older who had been relapse-free for at least five years and had no new MRI lesions for at least three years. Over two years, new clinical or MRI activity occurred in 4.7% of patients who continued DMT and 12.2% of those who discontinued treatment.
Clinical relapses were uncommon; the difference was driven mainly by new MRI lesions.
The DOT-MS trial included a somewhat younger population with inflammatory disease stability for more than five years. After discontinuation, significant inflammatory activity occurred in 8 of 45 patients — 17.8%, compared with 0 of 44 patients who continued treatment.
Again, most events were radiological rather than clinical.
In selected situations, switching to a less immunosuppressive therapy or individualizing treatment intervals may be considered.
For anti-CD20 therapies, observational data on extended dosing intervals have accumulated. This approach may be useful for selected stable patients, but it should not be treated as a universal replacement for the approved standard regimen.
Autologous haematopoietic stem cell transplantation is an intensive immune-reconstitution strategy, not simply another drug in the usual DMT sequence.
AHSCT is most appropriately considered in carefully selected patients with highly active relapsing MS, particularly when substantial inflammatory activity continues despite high-efficacy therapy.
Expected benefit is substantially lower when the disease process is predominantly non-inflammatory and progressive.
New neurological symptoms, confirmed relapses and recovery after relapses.
Walking, hand function, balance, cognition and evidence of gradual progression.
New T2/FLAIR activity, gadolinium-enhancing lesions when appropriate and establishment of a new MRI baseline.
The required laboratory monitoring depends on the mechanism of the new therapy and previous treatment exposure.
Particularly important during prolonged B-cell depletion or in patients with recurrent infections.
NfL and other biomarkers may supplement standard monitoring when available and appropriately interpreted.
The scan can be reviewed to determine whether the findings represent breakthrough activity and whether they justify changing treatment.
It is important to confirm that the event was a true relapse and to interpret it in relation to the current DMT and treatment timing.
Assessment should consider PIRA, possible transition to SPMS, ongoing inflammatory activity and alternative causes of functional decline.
In this situation, the next therapy should ideally be planned in advance to minimize rebound risk.
The balance between continuing the same treatment, de-escalation and switching to another therapy can be reassessed.
The strategy depends on disease activity and the current treatment and should usually be developed before conception.